Shouwen Wang, MD
Nephrology · Phoenix, AZNPI 1700889326
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,500 of the $6,543 with a category attached, or 68.8%. W. L. Gore & Associates, Inc. accounts for 90.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $4,600 and has fallen 91.0% since, to $414 in 2025.
Across 28 payments — averaging $233.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$6K
- Bard Peripheral Vascular, Inc.$179
- Johnson & Johnson$95
- Sonavex, Inc.$93
- Mallinckrodt Hospital Products Inc.$91
- Bayer$44
- plus $92 from 4 others
Across 23 payments — averaging $8214.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Laminate Medical Technologies Inc.$189K
What the payments were for
- Consulting fees$90014%
- Speaking & faculty fees$4,50069%
- Food & beverage$1,05216%
- Education$911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 16 | $5,949 |
| Bard Peripheral Vascular, Inc. | 2 | $179 |
| Johnson & Johnson(2 entities) | 2 | $95 |
| Sonavex, Inc. | 1 | $93 |
| Mallinckrodt Hospital Products Inc. | 1 | $91 |
| Bayer | 2 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Renalytix AI, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACUSEAL Vascular Graft$4,500
- Product in Development$1,016
- VIABAHN Endoprosthesis$212
- WAVELINQ$151
How this compares
$6,543 in reported general payments places this provider in the 85th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 53 | $353 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 47 | $230 |
| Prednisone | 51 | $88 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Phoenix
- Samer Bani HaniPhoenix$54K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Edgardo LaurelPhoenix$15K
- Sharareh SaadatPhoenix$15K
- Amar BistaPhoenix$12K
- Maher MousaPhoenix$9K
- Paul SacksPhoenix$8K
- William WeissPhoenix$8K
- Esmat MustafaPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.